Key facts
- It has raised $3.8M across 1 recorded rounds; the latest was Seed Round ($3.8M) in Dec 2024.
- Notable investors include The O.H.I.O. Fund.
- JucaBio has filed 1 Form D with the SEC, most recently Jan 2025 ($3.8M sold to 10 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for JucaBio
Funding rounds
1 roundsAbout JucaBio
Operator of a clinical-stage biopharmaceutical company intended to accelerate the development of novel therapeutics addressing significant unmet medical needs. The company offers a hub and spoke model with agile subsidiaries, deep drug development expertise, and a collaborative team culture, enabling biotech and pharmaceutical innovators to advance promising assets and demonstrate their value to patients, providers, and payers.
- Sector
- Business Products and Services (B2B)
- HQ
- Cincinnati, OH, United States
- Founded
- 2023
- Website
- jucabio.com/
- Ownership
- Privately Held (backing)
JucaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in JucaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on JucaBio in its N-PORT filings yet. We sweep new filings monthly.